22 April 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Department
Michał Machowski
1ABCDEF, Aisha Ou-Pokrzewińska1BCDEF, Katarzyna Perzanowska-Brzeszkiewicz 1BCDEF, Magdalena Gałecka-Nowak 1BDE, Szymon Pacho1BDE, Mateusz Jermakow 1BCDE*, Agnieszka Wójcik1BDE, Milena Zoruk1BDE, Andrzej Pruszczyk 1BDE, Karol Deutsch1BDE, Marek Roik 1BDE, Andrzej Łabyk 1BDE, Piotr Palczewski 2ABDEF, Piotr Pruszczyk 1ABCDEF
DOI: 10.12659/MSM.942612
Med Sci Monit 2024; 30:e942612
Table 5 Clinical course and outcome according to coexisting cardiovascular diseases.
| ACS (n=40) | APE (n=42) | AMyo (n=19) | COVID-19 (n=148) | P-value | Post-hoc | |
|---|---|---|---|---|---|---|
| Mechanical ventilation, n (%) | 6 (15.0) | 6 (14.3) | 2 (10.5) | 26 (17.6) | 0.847 | |
| Mortality, n (%) | 25.0 (10) | 21.4 (9) | 36.8 (7) | 23.0 (34) | 0.578 | |
| Length of stay [days] | 3.50 (2.0;7.8) | 9.00 (5.0;14.0) | 10.00 (3.0;13.5) | 10.00 (6.0;15.0) | <0.001 | ACS |
| ACS – acute coronary syndrome; AMyo – acute myocarditis; APE – acute pulmonary embolism; CAD – coronary artery disease; CHF – congestive heart failure; CRP – C-reactive protein; MEWS – Modified Early Warning Score. | ||||||